MYC and cancer: In cancer, dysregulation of the ubiquitination system frequently leads to abnormal stabilization of oncoproteins (e.g., c-Myc, Cyclin D1) or excessive degradation of tumor suppressors (e.g., p53, PTEN) (21, 22).